StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Pfizer (PFE) Commences Phase 3 Program for 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) Candidate, PF-06482077
December 14, 2018 8:01 AM
Pfizer Inc. (NYSE: PFE) announced today the initiation of a Phase 3 program for its 20-Valent pneumococcal conjugate vaccine (20vPnC) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Management Comments
Next Articles
Pfizer (PFE) Enters Strategic Research Collaboration & License Agreement with Kineta Immuno-Oncology to Develop New Cancer Immunotherapies
December 17, 2018 8:08 AM
Pfizer (PFE) Raises Quarterly Dividend 5.9% to $0.36, 3.3% Yield; Authorizes New $10B Buyback
December 14, 2018 12:11 PM
Pfizer Initiates Phase 3 Program for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older
December 14, 2018 8:00 AM
BMO Capital Reiterates Market Perform on Pfizer (PFE) Following Investor Meetings
December 13, 2018 7:34 AM
